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1. Introduction
  Microsized controlled drug delivery devices e.g. 
microemulsions and solid lipid microparticles (SLMs) 
have recently been proposed for different routes of drug 
administration. The composition of SLMs is equivalent to 
solid lipid nanoparticles (SLNs), but is in the micrometer 
size range. SLMs avoid the disadvantages of other particle 
carrier systems and offer the possibility of controlled drug 
release and drug targeting[1-4]. When optimized, SLMs 
exhibit high physicochemical stability, a high potential for 
large scale production and excellent biocompatibility[5] 
especially when natural lipids are concerned[6].
  Recently, lipid drug delivery systems are making waves 
in research due to their intrinsic advantages[5,6]. Yet 
as bulk materials, lipids crystallize immediately after 
preparation in higher energy modifications with more 
imperfections in the crystal lattice and at such may affect 
the functional properties of SLMs prepared. As a result, 
these systems suffer from low drug entrapment due to the 
crystalline nature of the solid lipids whether of natural or 
synthetic origin[7]. In addition, the presence of emulsifiers, 
the preparation method and the high-shear dispersion 
may account for changes in the crystallinity of matrix 
constituents compared with bulk materials. Lipid mixtures 
can result in increased or decreased crystallinity[8]. 
Objective: To preliminarily investigate three different lipid matrices consisting of two natural 
homolipids from Capra hircus (goat fat) and Bovine Spp. (tallow fat) and one semi-synthetic 
lipid (Softisan® 142) separately structured with Phospholipon® 90G (P90G) as potential 
delivery systems for poorly water soluble drugs. Methods: The structured lipid matrices were 
characterized by differential scanning calorimetry (DSC) and employed to prepare solid lipid 
microparticles (SLMs) by the melt homogenization method using gradient concentrations of 
polysorbate 80 and at different emulsification times of 2, 5 and 10 min using a Silverson mixer. 
The SLMs were analyzed for morphology and particle size, thermal properties, stability studies 
and determination of injectability. Results: The results showed that SLM production was optimum 
at 5 % of lipid matrices, 1.5 % of polysorbate 80 and emulsification time of 5 min. Increase in 
polysorbate 80 concentrations decreased the particle size of the SLMs. The SLMs were well formed, 
spherical, smooth and non-porous with particle sizes in the ranges of (13.90 ± 2.10) 毺m– (0.09 
± 0.01) 毺m for SLMs produced from the structured - tallow fat; (13.40 ± 1.30) 毺m– (0.10 
± 0.01) 毺m for the structured – goat fat and (13.40±2.00) 毺m– (2.10± 1.00)毺m for the 
structured Softisan® 142 lipid matrices. DSC traces showed that Softisan® 142 was the most 
crystalline of all three bulk matrices due to its high enthalpy (-7.962 mW/mg) while tallow fat 
was the least (-5.067 mW/mg) but addition of P90G to the matrices lowered their enthalpies 
mostly in the structured goat fat matrices. The SLMs when stored at 4-6 曟 were most stable and 
syringeable with 27 G needle. Conclusions: This suggests that structured goat fat matrices with 
the enthalpy of -2.813 mW/mg will mostly favour drug loading of some poorly soluble drugs more 
than tallow fat (-4.892 mW/mg) and Softisan® 142 (-5.501 mW/mg).
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Moreover, the addition of a second matrix component may 
somewhat alter the crystallization behaviour of the matrix. 
This may lead to amorphous or only partially crystallized 
metastable systems[7]. Polymorphic transformations may 
cause changes in active and auxiliary substance solubilities 
and melting points. In particular, the conversion of one 
polymorph into another may change the physical properties 
of the substance[2, 9, 10]. To overcome such a phenomenon, 
use of mixtures of lipids which do not form highly ordered 
arrangement is needed. Mixtures of lipids also modify 
polymorphic properties of the individual lipids and have 
been shown to generate lipid matrices of low crystallinity[11]. 
Here we report that the homolipids (goat fat and tallow fat) 
and semi-synthetic lipid (Softisan® 142) were separately 
modified with a heterolipid (P90G) at a ratio of 4 : 1 and 
characterized. These physically structured lipid matrices 
were formulated into SLMs with a gradient of polysorbate 
80 (0.00, 0.75, 1.50 and 2.00 % w/w, as the mobile 
surfactant) at various emulsification times (2, 5, 10 min) and 
characterized. 
  Homolipids and heterolipids have been lipidic excipients 
of interest in lipid drug delivery systems. Goat fat (Capra 
hircus) is ordinarily a waste product in abattoirs in Nigeria 
and represents a potential for drug delivery due to its crystal 
properties. It consists mainly of triglycerides and has been 
used in the formulation of self-emulsifying drug delivery 
systems[12, 13] and solid lipid nanodispersion[14]. Goat fat is 
a natural lipid and has good tolerability in vivo as well as 
having been shown to be stable to rancidity after degumming 
and deodorization[12, 15].
  Tallow fat (Bovine Spp.) is a solid fat extracted from the 
tissues and fatty deposits of animals, especially suet (the fat 
of cattle, sheep or oxen). It is white, odourless, tasteless and 
consists chiefly of triglycerides of oleic, stearic and palmitic 
acids. It has a wide range of industrial applications[16]. 
Tallow can be stored for extended periods without the need 
for refrigeration provided it is kept in an airtight container to 
prevent oxidation[16].
  Softisan® 142 is a semi-synthetic lipid consisting of 
hydrogenated coco-glycerides with wide application in 
drug and cosmetic delivery[17] whereas Phospholipon® 90G 
has been used in parenteral emulsions and in liposome 
formulation and has been reported as a good surface 
modifier[18-21]. This perhaps suggests that the bilayer 
structure of the phospholipids around the inner lipid 
core can enhance drug entrapment and further stabilize 
the particles especially when generated in an aqueous 
medium[20].
  Goat fat and tallow fat are natural homolipids used in food, 
pharmaceutical and other industries[12, 17] while Softisan® 
142 is semi-synthetic. They are highly crystalline and this 
adversely affects their drug loading capacities. Addition of 
a heterolipid, P90G is, however, expected to largely disturb 
the crystal arrangement and further modify the surface 
of the generated particles with the aim of improving their 
drug-holding capabilities and to ascertain the order of their 
possible utilization in the delivery of some poorly-water 
soluble drugs.
2. Materials and methods
2.1. Materials
  Phospholipon® 90G (P90G) (Phospholipid GmbH Köhn, 
Germany) is a purified, deoiled and granulated soy lecithin 
with phosphatidylcholine content of at least 90 %. Softisan® 
142 (Pastillen, Germany), sorbic acid (Fischer Co., New 
Jersey), sorbitol (BDH, England) and polysorbate 80 (Tween® 
80) (Uniqema, Belgium) were used as they were procured 
from their manufacturers without further purification. 
Homolipids (goat fat and tallow fat) were obtained from a 
batch processed in our Pharmaceutics laboratory according 
to an earlier procedure[12, 14]. Distilled water (Lion water, 
Nigeria) was used for SLM preparation.
2.2. Extraction of goat fat
  Goat fat was extracted from the adipose tissue of Capra 
hircus according to an earlier method[11, 12]. To summarize, 
the adipose tissue of Capra hircus was collected from freshly 
slaughtered goat, manually freed of extraneous materials, 
crushed and boiled in distilled water for 45 min, filtered 
through a muslin cloth and allowed to solidify at room 
temperature. The solid fat was manually removed and 
bleached/deodourized by passing it through a mixture of 
activated charcoal and bentonite (2 : 1) at 100 曟 at a ratio 
of 10 g of the fat and 1 g of the column material. 
  The above procedure was also applied to extract tallow fat 
from Bovine spp.
2.3. Differential scanning calorimetry (DSC)
  The thermal behaviour was determined using a DSC 
(NETZSCH DSC 204 F1, Germany) with an empty standard 
aluminum pan used as reference. DSC scans were recorded 
at heating rates of 10 曟/min between 35 曟 and 190 曟 under 
a 20 mL/min nitrogen flux with sample size of 3-5 mg. The 
DSC thermograms of pure goat fat, tallow fat, and Softisan® 
142, as bulk materials, and mixtures with P90G and SLMs 
were assessed. All determinations were baseline-corrected.
2.4. Formulation of the lipid matrix
  The lipid matrix used in the formulation corresponded to a 
4 : 1 mixture of goat fat and P90G; tallow fat and P90G and 
Softisan® 142 and P90G respectively and were prepared by 
fusion. The lipids were weighed with an electronic balance 
(Mettler H8, Swizerland), melted together at 60 曟 on a 
thermo-regulated water bath shaker (Heto, Denmark) and 
stirred until solidification.
2.5. Formulation of solid lipid microparticles (SLMs)
  SLMs were formulated to contain 5 % w/w of the previously 
molten lipid matrices (i.e. 4 : 1 mixture of goat fat and 
P90G; tallow fat and P90G and Softisan® 142 and P90G), 
gradients of polysorbate 80 (0.00, 0.75, 1.50, and 2.00 % 
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w/w), 4.00 % w/w of sorbitol, 0.10 % w/w of sorbic acid 
and enough distilled water to make 100.00 % w/w.  The 
hot homogenization method was adopted. In each case, the 
lipid matrix was melted at 60 曟 and the aqueous phase 
containing polysorbate 80, sorbitol and sorbic acid at the 
same temperature was added to the molten lipid matrix and 
stirred gently with a magnetic stirrer (SR 1UM 52188, Remi 
Equip., India). The mixture was further dispersed with a 
mixer (Silverson L4R, Adelphi Manufac., England) at 6 200 
rpm for different emulsification times (2, 5, and 10 min) to 
produce the hot primary emulsion which was collected in 
pre-warmed containers and allowed to recrystallize at room 
temperature. 
2.6. Morphology and particle size analysis
  Particle size analysis was carried out on the SLMs within 
one week of production using a digital light microscope 
(Leica Diestar, Germany) and images captured with a 
Moticam 1000 camera. The morphology (shape and surface) 
and size of the particles were also noted. The SLMs were 
subjected to time-resolved particle size analyses for 12 
months at 6 month intervals to check the effect of storage on 
particle size.
2.7. Thermal properties of the SLMs (DSC)
  The thermal behaviour of the SLMs was assessed using 
a DSC (NETZSCH DSC 204 F1, Germany) with an empty 
standard aluminum pan used as reference. DSC scans were 
recorded after baseline-correction at heating rates of 10 曟
/min between 35 and 190 曟 under a 20 mL/min nitrogen 
flux with sample size of 3 - 5 mg.
2.8. Stability studies of the formulations
  The physical stability of the microparticles was evaluated 
for 12 months under different temperature conditions. Some 
6 mL volumes of each SLM batch were stored in closed glass 
bottles and placed at 4-6 曟 and 25 曟 out from direct 
light. Aliquot samples were withdrawn every 6 months to 
determine particle size and morphology as described above. 
2.9. Determination of injectability
  Injectability, defined as the smallest needle gauge that 
a microparticle sample can pass through was determined 
according to the previously reported method [13] The 
injectability was determined by pushing 4 mL of sample 
from a 5 mL plastic disposable syringe through hypodermic 
needles ranging from 18 to 27 guage within 20 sec. The 
formulation was first tested using the smallest needle (27 
G). If the entire content of the sample passed through a 27 
G needle, its injectability was recorded as 27 otherwise, the 
study was repeated using 25 G needle, followed by the next 
smaller gauge needle.
2.10. Statistical analysis
  All experiments were performed in replicates for validity 
of statistical analysis. Results were expressed as mean±SD 
ANOVA and student’s t-test were performed on the data 
sets generated using SPSS. Differences were considered 
significant for P-values < 0.05– 0.001.         
3. Results 
3.1. Differential scanning calorimetry
  The DSC results are shown in Figures 1-9. The melting 
endotherm for goat fat showed a transition endothermic peak 
at 53.7 曟 with an enthalpy of -6.420 mW/mg (Figure 1) 
while its corresponding P90G-structured matrix exhibited 
a melting peak at 50.8 曟 with an enthalpy of -2.813 mW/
mg (Figure 2). The DSC trace of tallow fat was 54.5 曟 with 
an enthalpy of -5.067 mW/mg (Figure 3) and that of the 
structured matrix was 52.2 曟 with an enthalpy of -5.501 
mW/mg (Figure 4). The DSC thermogram of Softisan® 142 
showed an endothermic peak at 46.8 曟 with an enthalpy 
of -7.962 mW/mg (Figure 5) and that of its corresponding 
structured matrix was 43.3 曟 with an enthalpy of -4.892 
mW/mg (Figure 6). Here we observed a melting point 
value for goat fat that was slightly different from that in the 
literature reported by Attama and Muller-Goymann, 2006 
and the possible reason may be a question of sensitivity of 
the DSC machine used. 
  SLMs prepared from these matrices generally showed 
increased endothermic temperatures which may be due 
to the presence of other formulation excipients such as 
polysorbate 80, sorbic acid and/or sorbitol. The DSC traces 
for the SLMs formulated with the structured goat fat showed a 
wide peak at 118.1 曟 with an enthalpy value of -12.1 mW/
mg (Figure 7) while the DSC traces of the SLMs prepared from 
P90G-structured tallow fat matrix indicated two endothermic 
transitions which occurred at 104.4 曟with an enthalpy of 
-13.31 mW/mg and at 108.8 曟 with an enthalpy of -14.67 
mW/mg for the higher peak (Figure 8). Normally, the highest 
peak is attributed to a stable modification whereas the 
fraction responsible for the lower peak is attributed to an 
unstable modification [11]. The SLMs formulated using the 
structured-Softisan® 142 showed a peak endothermic 
temperature at 104.3 曟 with an enthalpy of -16.58 mW/mg 
(Figure 9). 
3.2. Physicochemical properties 
  The result of the particle size analysis for the optimized 
SLMs is presented in Table 1. Optimum concentration of 
1.5 % w/w concentration of polysorbate 80 was employed 
in the SLM production at the emulsification time of 5 min. 
The SLMs obtained were uniformly dispersed with uniformly 
sized particles. For all the SLM formulations, significant 
differences in particle size were observed after 10 minutes. 
The microparticulate dispersions were stable, odourless and 
did not show sedimentation even after centrifugation (3 000 
rpm for 90 min). 
3.3. Morphology and particle size analysis
  The particle sizes within one week of formulation were in the 
range of (13.90 ± 2.10) 毺m–(0.09 ± 0.01) 毺m for the 
structured - tallow fat; (13.40 ±1.30) 毺m–(0.10 ± 0.01) 滋
m for the structured–goat fat and (13.40 ± 2.00) 毺m–(2.10 
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±1.00) 毺m for the structured Softisan® 142 lipid matrices 
(Table 1). Time resolved particle size analysis showed that the 
SLMs increased in size probably due to crystallization of the 
previously molten lipid matrices[11, 14]. This tendency was most 
pronounced in the SLMs formulated from the structured-goat 
fat matrices (25.3±5.3) 毺m followed by tallow fat (19.4 ± 
2.8) 毺m and Softisan® 142 (17.5±2.0) 毺m.
  The microparticles clearly show a homogeneous monolayer 
coating of the surfactant at the periphery of the lipid core 
(Figure10). Upon storage, the shape of the SLMs remained 
intact (spherical) in the dispersions obtained from P90G-
structured goat and tallow fat matrices according to the 
observation by Kim et al[6]. However, the SLMs obtained 
from P90G-structured Softisan® 142 slightly changed 
becoming somewhat crystal-like which may point towards 
higher crystallinity. 
3.4. Stability studies of the formulations
  Storing the formulations at 4-6 曟 and 25 曟 did not make 
the SLMs sediment. The formulations remained uniformly 
dispersed. However, the samples stored at 4-6 曟 appeared 
better than those at 25 曟. This suggests that there was 
slight crystal growth at ambient temperature especially in 
the formulation made from P90G-structured Softisan® 142 
matrices.
3.5. Determination of injectability
  To further confirm the observed crystal growth at room 
temperature, the samples stored at this temperature were 
not syringeable with 27 G needle after 6 months whereas 
those at 4-6 曟remained syringeable (27 G) even up to 
12 months. By implication, the SLMs were best stored at 
4-6 曟. However, their being syringeable may suggest a 
potential for parenteral drug delivery. 
Figure 4. DSC thermogram of P90G-
structured tallow fat matrix.
Figure 5. DSC thermogram of pure Softisan® 
142.
Figure 6. DSC thermogram of P90G-
structured Softisan® 142 matrix.
Figure 7 .  DSC thermogram o f  SLM 
formulation based on P90G-structured goat 
fat matrix.
Figure 8 .  DSC thermogram o f  SLM 
formulation based on P90G-structured tallow 
fat matrix.
Figure 9 .  DSC thermogram o f  SLM 
formulation based on P90G-structured 
Softisan® 142.
Figure 1. DSC thermogram of goat fat. Figure 2. DSC thermogram of P90G-
structured goat fat matrix.
Figure 3. DSC thermogram of tallow fat.
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Table 1
Effects of different polysorbate concentrations and emulsification times on SLM mean diameter.  
Formulation
Polysorbate 80
 percentage (w/w)
Emulsification time 
 (min)
Particle mean diameter ± SD (毺m).
Goat fat and P90G Tallow fat and P90G Softisan®142  and  P90G
SLM 1a 0.75 2  13.40±1.30 13.90±2.10       13.4±2.0
SLM 1b 0.75 5  12.9 0±1.00 12.80±1.20       12.8±1.2
SLM 1c 0.75 10  10.10±0.75  10.00±1.00       10.5±1.0
SLM 2a 1.50 2    8.60±2.00   8.00±2.40        8.9±2.2
SLM 2b 1.50 5  5.30±2.50 5.50±2.50       5.0±2.5
SLM 2c 1.50 10 3.50±2.20 2.00±1.20      2.1±1.0
SLM 3a 2.00 2 0.10±0.01 0.09±0.01 ND
SLM 3b 2.00 5 ND  ND ND
SLM 3c 2.00 10 ND ND ND
ND implies not determined. Results are the mean of 3 measures±SD. 
Figure 10. Photomicrographs of SLM 2b (伊100) 12 h after formulation (A, C,  E) and 6 months of storage (B, D, F).
4. Discussion
  We observed that an increase in polysorbate 80 concentration 
reduced the particle size of the SLMs. At 2.00 % w/w of 
polysorbate 80, the particle size was difficult to determine 
possibly due to the fact that they were no longer within the 
micrometer range. Higher emulsification times of 10 min 
generally produced smaller but gelled SLMs making them 
unpleasant for intending-orally actives. They may however 
be more relevant in topical and transdermal drug delivery 
systems as their minute particles would not present any 
coarse feel. The formulations containing 0.75 % w/w of 
polysorbate 80 generally had some un-emulsified entities 
(otherwise called dead-ends) at 2 min emulsification times. 
This made it impossible for this concentration to be selected 
for subsequent production. Even when the emulsification 
time was increased to 5 or 10 min, there was still separation 
probably due to the small concentration of the surfactant 
(0.75 %) not being able to completely lower the interfacial 
tension to prevent partitioning of the particles. However, 
the optimized SLMs were spherical in shape with smooth 
surfaces and a ring of the surfactant coat on the inner core. 
  Mixtures of lipids modify the properties of the individual 
lipids. We observed that the structuring of these bulk 
crystalline matrices with P90G generally produced matrices 
with lower melting endotherms as well as enthalpies. 
Reduction in enthalpy generally suggests less crystallinity 
of the lipid matrices[11]. This is perhaps due to the presence 
of the unsaturated phospholipid molecules of P90G in the 
ordered structures of the matrices that caused a broadening 
and a shift of the solid lipid–to–liquid crystal transition 
peak towards lower temperatures. In other words, the varied 
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fatty acid contents of these lipids may have interacted in 
such a manner as to partly disorder the crystal arrangement 
of the individual lipids since their fatty acids vary widely in 
chain length and degree of saturation[11, 14]. Our observation 
therefore, agrees with the current literature that has 
proved P90G as a good surface modifier for solid lipid 
particles[17, 18] with possible improvement in targeting and 
pharmacokinetics[21-23] whereby the phospholipids bilayer 
structure formed around the lipid core may increase the drug 
loading capacity, as biologically important molecules can 
be anchored on the colloidal particle surfaces, and surface-
modification also enables stabilization of colloidal particles 
especially when generation of the microparticles is carried 
out in an aqueous medium[19].
 The decrease in enthalpy between the SLMs produced 
using the P90G-structured goat fat suggests that they 
were less crystalline than those of P90G-structured tallow 
fat. Further comparison with the SLMs obtained from the 
structured-Softisan® 142 suggests that the latter was the 
most crystalline of all. This is because the SLMs from the 
structured Softisan® 142 matrices showed the highest 
enthalpy value of -16.58 mW/mg. The increase in enthalpy 
confirms high amounts of crystals upon storage due to 
delayed crystallization from fractions of a supercooled 
amorphous melt. This was further confirmed by the shape 
of the SLMs after 6 months storage which was somewhat 
crystal-like and/or prismatic. 
  We, therefore, conclude that SLMs were successfully 
prepared by the hot homogenization method which is 
simple, reproducible, scaleable and cheap. The optimized 
processing parameters have shown that lipid structuring 
modifies the properties of the individual lipids and may 
increase or decrease crystallinity. Our observation shows 
that structuring of goat and tallow fats (natural homolipids) 
achieved larger distortions in the crystal arrangement 
of their matrices than with structured-Softisan® 142 
(semi-synthetic homolipid) matrix thereby creating 
numerous defects/spaces for possible drug localization. 
Yet, structured-goat fat matrices (at the analyzed ratio 
combinations) demonstrated the best potentials for use as 
an SLM drug delivery system among the three investigated 
matrices followed by the structured- tallow fat matrices. 
By implication, they can be employed as SLM carriers to 
orally deliver some poorly water-soluble drugs belonging to 
biopharmaceutical classification scheme (BCS) classes II and 
III. 
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